<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id><journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id><journal-title-group><journal-title>BMC Research Notes</journal-title></journal-title-group><issn pub-type="epub">1756-0500</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31924273</article-id><article-id pub-id-type="pmc">6954499</article-id><article-id pub-id-type="publisher-id">4877</article-id><article-id pub-id-type="doi">10.1186/s13104-019-4877-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Note</subject></subj-group></article-categories><title-group><article-title>E-test versus agar dilution for antibiotic susceptibility testing of <italic>Helicobacter pylori</italic>: a comparison study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Miftahussurur</surname><given-names>Muhammad</given-names></name><address><email>muhammad-m@fk.unair.ac.id</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Fauzia</surname><given-names>Kartika Afrida</given-names></name><address><email>kartikafauzia@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nusi</surname><given-names>Iswan Abbas</given-names></name><address><email>iswan-a-n@fk.unair.ac.id</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Setiawan</surname><given-names>Poernomo Boedi</given-names></name><address><email>poernomo.boedi@fk.unair.ac.id</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Syam</surname><given-names>Ari Fahrial</given-names></name><address><email>ari_syam@hotmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Waskito</surname><given-names>Langgeng Agung</given-names></name><address><email>langgengaw@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Doohan</surname><given-names>Dalla</given-names></name><address><email>doctordoohan@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ratnasari</surname><given-names>Neneng</given-names></name><address><email>nenengratnasari@yahoo.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Khomsan</surname><given-names>Ali</given-names></name><address><email>erlangga259@yahoo.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Adnyana</surname><given-names>I. Ketut</given-names></name><address><email>ketut@fa.itb.ac.id</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Akada</surname><given-names>Junko</given-names></name><address><email>akadajk@oita-u.ac.jp</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yamaoka</surname><given-names>Yoshio</given-names></name><address><email>yyamaoka@oita-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.440745.6</institution-id><institution>Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, </institution><institution>Universitas Airlangga, </institution></institution-wrap>Jalan Mayjend Prof. Dr. Moestopo No. 6-8 Surabaya, Surabaya, 60131 Indonesia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.440745.6</institution-id><institution>Institute of Tropical Disease, </institution><institution>Universitas Airlangga, </institution></institution-wrap>Surabaya, 60115 Indonesia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0665 3553</institution-id><institution-id institution-id-type="GRID">grid.412334.3</institution-id><institution>Department of Environmental and Preventive Medicine, </institution><institution>Oita University Faculty of Medicine, </institution></institution-wrap>Yufu, Oita 879-5593 Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000000120191471</institution-id><institution-id institution-id-type="GRID">grid.9581.5</institution-id><institution>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, </institution><institution>University of Indonesia, </institution></institution-wrap>Jakarta, 10430 Indonesia </aff><aff id="Aff5"><label>5</label>Department of Internal Medicine, Faculty of Medicine Gadjah, Mada University-Dr. Sardjito, Yogyakarta, 55281 Indonesia </aff><aff id="Aff6"><label>6</label>Department of Community Nutrition, Bogor Agriculture University, Bogor, 16680 Indonesia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1808 0563</institution-id><institution-id institution-id-type="GRID">grid.434933.a</institution-id><institution>School of Pharmacy, </institution><institution>Bandung Institute of Technology, </institution></institution-wrap>Bandung, 40132 Indonesia </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0665 3553</institution-id><institution-id institution-id-type="GRID">grid.412334.3</institution-id><institution>Global Oita Medical Advanced Research Center for Health, </institution><institution>Oita University, </institution></institution-wrap>Oita, 870-1192 Japan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution>Department of Medicine, Gastroenterology and Hepatology Section, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX 77030 USA </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>13</volume><elocation-id>22</elocation-id><history><date date-type="received"><day>7</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">For evaluating the antibiotic resistance of <italic>Helicobacter pylori</italic>, the agar dilution method is the gold standard; however, using this method in daily practice is laborious. E-test has been proposed to be an uncomplicated method. This study was aimed at validating the E-test and detecting the presence of any bias between the agar dilution method and E-test.</p></sec><sec><title>Results</title><p id="Par2">The agar dilution method and E-test were performed using five antibiotics for 72 strains of <italic>H. pylori</italic> obtained from clinical patients in Indonesia. The E-test&#x02019;s results showed a higher prevalence of resistance to all the antibiotics tested but the difference was not significant. Results showed high essential agreement (&#x0003e;&#x02009;90.0%) for all the antibiotics, but only 84.7% for metronidazole. The agreement for MIC value was acceptable for levofloxacin, clarithromycin, and metronidazole. For amoxicillin, it showed only fair agreement (0.25) by the Kappa analysis and significant difference by Passing-Bablok regression. Even though some discrepancies were found, the E-test has an acceptable agreement for levofloxacin, metronidazole, tetracycline, and clarithromycin but further confirmation may be necessary for amoxicillin.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>E-test</kwd><kwd>Agar dilution</kwd><kwd><italic>Helicobacter pylori</italic></kwd><kwd>Antibiotic susceptibility test</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK62813</award-id><principal-award-recipient><name><surname>Yamaoka</surname><given-names>Yoshio</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>15H02657</award-id><award-id>16H05191</award-id><award-id>16H06279</award-id><award-id>18KK0266</award-id><award-id>19H03473</award-id><principal-award-recipient><name><surname>Yamaoka</surname><given-names>Yoshio</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>Africa-Asia Science Platform</award-id><principal-award-recipient><name><surname>Yamaoka</surname><given-names>Yoshio</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010447</institution-id><institution>Kementerian Riset, Teknologi dan Pendidikan Tinggi</institution></institution-wrap></funding-source><award-id>123.4/D2.3/KP/2018</award-id><principal-award-recipient><name><surname>Miftahussurur</surname><given-names>Muhammad</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par9"><italic>Helicobacter pylori</italic> virulent strains being predominant in several regions thus <italic>H. pylori</italic> should always be treated regardless of the presence of symptoms [<xref ref-type="bibr" rid="CR1">1</xref>]. However, antibiotic resistance caused in <italic>Helicobacter pylori</italic> eradication failure and the resistance rates widely vary around the world [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Recent hospital-based study in Japan reporting 48% of clarithromycin resistance [<xref ref-type="bibr" rid="CR5">5</xref>] while our previous study in Indonesia reported a 9% resistant rate [<xref ref-type="bibr" rid="CR6">6</xref>]. Because of such differences, the Maastricht Consensus Report on <italic>H. pylori</italic> infection has stated that antibiotic susceptibility tests with periodic monitoring should be performed in each region to determine the most suitable therapy for a given population [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par10">Given the importance of antibiotic susceptibility testing for <italic>H. pylori</italic>, it is crucial to choose a testing method that delivers high accuracy and feasible for clinical settings. According to the Clinical and Laboratory Standards Institute (CLSI), direct measurement with the agar dilution method (ADM) is the gold standard for <italic>H. pylori</italic> [<xref ref-type="bibr" rid="CR7">7</xref>]. However, ADM requires laborious preparation and may not cost and time-effective for daily clinical practices [<xref ref-type="bibr" rid="CR8">8</xref>]. An alternative, relatively simple method is the E-test, which uses different concentrations of antibiotics in a single strip.</p><p id="Par11">In the present study, we followed CLSI guideline EP-09 to compare the measurement procedures and estimate bias [<xref ref-type="bibr" rid="CR9">9</xref>]. These methods have been applied in other studies, but rarely for <italic>H. pylori</italic> [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Thus, a study using isolates from the Indonesian population, an area with the variable prevalence and virulence type of <italic>H. pylori</italic> [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] may provide another insight of the E-test reliability.</p><p id="Par12">This study aimed to examine the susceptibility of Indonesian <italic>H. pylori</italic> isolates to five antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin), using ADM as the gold standard to validate the level of agreement and reliability of the E-test.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Patients and H. pylori isolates</title><p id="Par13">We analyzed a total of 72 clinical <italic>H. pylori</italic> isolates obtained from adult dyspeptic patients as part of a nationwide survey in Indonesia and reference strain ATCC26695. Data for the E-test results for the 72 strains were published in our previous study [<xref ref-type="bibr" rid="CR6">6</xref>]. Isolate storage and all the susceptibility tests were conducted at the Department of Environment and Preventive Medicine, Oita University Faculty of Medicine, Yufu, Japan.</p><p id="Par14">All the patients from whom the isolates were obtained provided written informed consent, and the study protocol was approved by the Institutional Review Board or Ethics Committee of Dr. Cipto Mangunkusumo Teaching Hospital (Jakarta, Indonesia), Dr. Soetomo Teaching Hospital (Surabaya, Indonesia), Dr. Wahidin Sudirohusodo Teaching Hospital (Makassar, Indonesia), and Oita University Faculty of Medicine (Yufu, Japan).</p></sec><sec id="Sec5"><title>Antibiotic susceptibility testing by ADM and E-test</title><p id="Par15">The procedure for ADM followed the protocol described by CLSI [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Briefly, around 2&#x000a0;&#x000b5;L of bacterial suspension with 0.5 McFarland concentration was inoculated into Mueller&#x02013;Hinton agar contained twofold dilutions of antibiotics. E-test (bi&#x000f3;Meurieux, La Balme-Les-Grottes, France) procedure was reported previously, following manufacturer instructions [<xref ref-type="bibr" rid="CR6">6</xref>]. Briefly, 100&#x000a0;&#x000b5;L of <italic>H. pylori</italic> suspension with 3 McFarland standard was inoculated into Mueller&#x02013;Hinton agar plate without antibiotic and one E-test strip were applied to the center of the plate. incubation under microaerophilic conditions for 72&#x000a0;h. A full explanation of the method is available in the Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par16">The ADM is the gold standard for antibiotic susceptibility test, thus the results were used as the reference for validating the E-test method. The samples were grouped into &#x0201c;sensitive&#x0201d; and &#x0201c;resistant&#x0201d; according to the EUCAST clinical breakpoint criteria [<xref ref-type="bibr" rid="CR16">16</xref>] and were then used to evaluate, essential agreement, Cohen&#x02019;s kappa analysis, McNemar, also the major and very major error rate between the two methods. The analysis was performed using the SPSS statistical software version 23.0 (IBM Corp., Armonk, NY, USA).</p><p id="Par17">To better understand the agreement of the MIC results, we followed CLSI guideline EP-09 to use the non-parametric approach proposed by Bland and Altman with Krouwer modification because the gold standard is available [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Scatter plot and Passing&#x02013;Bablok analyses were also performed using R environment ver. 3.5.1 with the mcr package [<xref ref-type="bibr" rid="CR19">19</xref>]. Receiver operating characteristic analysis was used to evaluate the sensitivity, specificity, and area under the curve (AUC) of the E-test results relative to those of the ADM.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Susceptibility results of the ADM and E-test</title><p id="Par18">We initially attempted to culture 77 strains of <italic>H. pylori</italic>; however, five strains did not grow and were excluded. This growth failure number was still acceptable according to the U.S. Food and Drug Administration (FDA) recommendation for antimicrobial susceptibility testing [<xref ref-type="bibr" rid="CR20">20</xref>]. Both the ADM and E-test were applied to the same 72 remaining strains.</p><p id="Par19">In Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, both ADM and the E-test showed high resistance rates to metronidazole and levofloxacin. Slightly higher resistant rates were shown by the E-test for four antibiotics, but this difference was not statistically significant (McNemar test: amoxicillin, <italic>P</italic>&#x02009;=&#x02009;0.99; metronidazole, <italic>P&#x02009;</italic>=&#x02009;0.55; clarithromycin, <italic>P</italic>&#x02009;=&#x02009;0.63; and levofloxacin, <italic>P</italic>&#x02009;=&#x02009;0.99; the value for tetracycline could not be calculated because of the zero percentage result). MIC50 and MIC90 were the same for all the antibiotics except amoxicillin and tetracycline.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Resistance rates according to the agar dilution method (ADM) and E-test</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Antibiotic</th><th align="left" rowspan="2">Clinical breakpoint (mg/L)</th><th align="left" colspan="2">Resistance rate (%) n&#x02009;=&#x02009;72</th><th align="left" colspan="2">MIC50<sup>a</sup> (mg/L)</th><th align="left" colspan="2">MIC90<sup>a</sup> (mg/L)</th><th align="left">Essential agreement (%)</th><th align="left">Kappa coefficient</th><th align="left">95% confidence<break/>interval</th></tr><tr><th align="left">ADM</th><th align="left">E-test</th><th align="left">ADM</th><th align="left">E-test</th><th align="left">ADM</th><th align="left">E-test</th><th align="left"/><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left">Amoxicillin</td><td align="left">&#x0003e; 0.125</td><td align="left">3/72 (4.2)</td><td align="left">4/72 (5.6)</td><td char="." align="char">0.032</td><td char="." align="char">0.016</td><td char="." align="char">0.064</td><td char="." align="char">0.125</td><td char="." align="char">93.1</td><td align="left">0.25</td><td align="left">&#x02212;&#x02009;0.38 to 0.88</td></tr><tr><td align="left">Metronidazole</td><td align="left">&#x0003e; 8</td><td align="left">30/72 (41.7)</td><td align="left">33/72 (45.8)</td><td char="." align="char">8</td><td char="." align="char">8</td><td char="." align="char">64</td><td char="." align="char">64</td><td char="." align="char">84.7</td><td align="left">0.69</td><td align="left">0.52 to 0.85</td></tr><tr><td align="left">Clarithromycin</td><td align="left">&#x0003e; 0.5</td><td align="left">3/72 (4.2)</td><td align="left">5/72 (6.9)</td><td char="." align="char">0.032</td><td char="." align="char">0.032</td><td char="." align="char">0.25</td><td char="." align="char">0.25</td><td char="." align="char">94.4</td><td align="left">0.47</td><td align="left">&#x02212;&#x02009;0.29 to 0.97</td></tr><tr><td align="left">Levofloxacin</td><td align="left">&#x0003e; 1</td><td align="left">18/72 (25.0)</td><td align="left">19/71 (26.4)</td><td char="." align="char">0.25</td><td char="." align="char">0.25</td><td char="." align="char">8</td><td char="." align="char">8</td><td char="." align="char">93.1</td><td align="left">0.81</td><td align="left">0.66 to 0.97</td></tr><tr><td align="left">Tetracycline</td><td align="left">&#x0003e; 1</td><td align="left">0/72 (0.0)</td><td align="left">2/71 (2.8)</td><td char="." align="char">0.125</td><td char="." align="char">0.064</td><td char="." align="char">0.5</td><td char="." align="char">0.25</td><td char="." align="char">97.2</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>MIC50/MIC90: minimum inhibitory concentrations that inhibited 50 and 90% of the isolates. For comparability with ADM, the upper limits were set as 1&#x000a0;mg/L for amoxicillin, 2&#x000a0;mg/L for clarithromycin and tetracycline, 8&#x000a0;mg/L for levofloxacin, and 64&#x000a0;mg/L for metronidazole, and the lower limits were set as 0.016&#x000a0;mg/L for amoxicillin, 0.032&#x000a0;mg/L for clarithromycin and tetracycline, 0.125&#x000a0;mg/L for levofloxacin, and 1&#x000a0;mg/L for metronidazole</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Agreement of the susceptibility results</title><p id="Par20">To determine the precision and reliability of the E-test. Differences in the &#x0201c;sensitive&#x0201d; and &#x0201c;resistant&#x0201d; interpretations were further analyzed according to the agreement percentage and Cohen&#x02019;s kappa analysis (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The kappa values showed fair agreement for amoxicillin, moderate for clarithromycin, and substantial agreement for metronidazole and levofloxacin prevalence by ADM. The kappa value for tetracycline could not be evaluated because of the zero value for prevalence.</p></sec><sec id="Sec10"><title>Measurement of errors</title><p id="Par21">Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the major errors and very major errors, as described in previous studies [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. For all the antibiotics, the very major error rate was lower than the major error rate. Despite its low resistance rate according to both the ADM and E-test (4.2 and 5.6%, respectively), amoxicillin was associated with a very major error rate of 2.78% and a major error rate of 4.17%. Metronidazole also had a high very major error and major error rates (5.56 and 9.72%, respectively).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The major error and very major error rates in categorical agreement. A very major error was defined as when a strain that was resistant according to ADM was assessed as &#x0201c;sensitive&#x0201d; by the E-test; this may result in the patient not receiving effective antibiotics, allowing the infection to continue. A major error was defined as when the strain was sensitive according to ADM but assessed as &#x0201c;resistant&#x0201d; by the E-test. True sensitive is sensitive percentage minus very major error rate while the true resistant is resistant percentage minus major error rate</p></caption><graphic xlink:href="13104_2019_4877_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec11"><title>Analysis of agreement and systematic bias</title><p id="Par22">The modified Bland&#x02013;Altman difference plots [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] to assess the limit of agreement and any pattern of bias are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. For all the antibiotics except tetracycline, the median difference in measured MIC was zero, indicating there was no constant bias between the E-test and ADM. At low MIC values, the differences in the plots tended to clump around the median value, indicating precision between the methods. The error tended to increase at higher values of MIC for all the antibiotics, shown by the greater difference values. Spearman correlation analysis confirmed this correlation was significant for amoxicillin (r&#x02009;=&#x02009;0.53, <italic>P</italic>&#x02009;&#x02264;&#x02009;0.001), clarithromycin (r&#x02009;=&#x02009;0.56, <italic>P</italic>&#x02009;&#x02264;&#x02009;0.001), and tetracycline (r&#x02009;=&#x02009;0.76, <italic>P</italic>&#x02009;&#x02264;&#x02009;0.001).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Bland&#x02013;Altman difference plots comparing the minimum inhibitory concentration (MIC) results of the agar dilution method and E-test for the five antibiotics. The plots use the modification of Krouwer [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The plots confirm that the measurements by both methods were equal for all the antibiotics, except for tetracycline. For tetracycline, the median difference was 0.061&#x000a0;mg/L</p></caption><graphic xlink:href="13104_2019_4877_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par23">As recommended by the CLSI, Passing&#x02013;Bablok regression analysis was used to estimate the analytical method agreement and detecting the presence of any bias. It can determine whether the E-test procedure and agar dilution method can be used interchangeably. In the Passing&#x02013;Bablok regression plots (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig.&#x000a0;S1), the confidence intervals for the intercepts for all the antibiotics except amoxicillin and tetracycline included zero, indicating there were no significant proportional differences between the values measured by the two methods. The confidence intervals for the slopes included the value 1 (indicating no significant difference between the measurements) for all the antibiotics except amoxicillin and tetracycline.</p></sec><sec id="Sec12"><title>Accuracy of the E-test</title><p id="Par24">The sensitivity, specificity, and AUC of the E-test for distinguishing the strains resistant to each antibiotic were calculated. For amoxicillin resistance, the E-test showed low sensitivity but high specificity (33.3 and 95.7%), with a good AUC value (0.783). For clarithromycin, the sensitivity was also low (66.7%) but the specificity and AUC were high (95.7 and 0.937%, respectively). For metronidazole and levofloxacin, the E-test showed quite high sensitivity (86.7 and 88.9%, respectively), specificity (83.3 and 94.4%), and AUCs (0.887 and 0.919). It was not possible to make these calculations for tetracycline because ADM showed the resistance rate was zero.</p></sec></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par25">This is the first study to evaluate the validity of the E-test as an alternative method for the detection of resistant strains of <italic>H. pylori</italic> in Indonesia. E-test is preferable in clinical practice due to the lower cost and less time consuming [<xref ref-type="bibr" rid="CR8">8</xref>]. Several previous studies have validated the E-test for European populations [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>], Brazilian children [<xref ref-type="bibr" rid="CR13">13</xref>] and American [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par26">In this study, we found that the resistance rate obtained from E-test showed a slightly higher discrepancy compared to ADM, although this was statistically not significant according to McNemar analysis; similar to previous studies [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. For levofloxacin, metronidazole, and clarithromycin, the essential agreement was in the acceptable range according to the FDA (&#x0003e;&#x02009;90%) with low major error and very major error rates [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Agreement for MIC values with Bland&#x02013;Altman and Passing-Bablok also showed that both methods can be used interchangeably with good sensitivity and specificity [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par27">However, consistent with other studies, metronidazole showed a low essential agreement and high very major error rate, but metronidazole resistance is common and is not a first-line treatment so its use is limited [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The emergence of heteroresistance to metronidazole within a mixed colony may have played an important role in this result [<xref ref-type="bibr" rid="CR24">24</xref>]. For amoxicillin, Cohen&#x02019;s kappa analysis only showed a fair agreement. Moreover, a non-significant correlation for Passing-Bablok and very low sensitivity might indicate the lower reliability of the E-test for measuring amoxicillin resistance, compared to other antibiotics. However, it also probably due to a very low prevalence of amoxicillin resistant thus limit the kappa analysis in estimating values, known as the &#x0201c;kappa paradox&#x0201d; [<xref ref-type="bibr" rid="CR29">29</xref>]. Hence, amoxicillin is included in the first line regiment and the non-concordance that occurred may affect the treatment choice and patient&#x02019;s outcome [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par28">The reason for the discrepancy observed in the E-test results was still unknown but is probably the result of several factors. The procedure for storing E-test strips may affect the drug concentration, and incubation in a microaerophilic environment may influence the activity of the antibiotic, especially for macrolides [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The large bacterial inoculum size was tested by an E-test strip while in ADM, small number of bacteria were inoculated on agar plates containing antibiotics. The difference in bacteria/antibiotics ratio may have resulted in higher growth capabilities of the strain, resulting in a higher measured resistance rate in the E-test than ADM. Indeed, it has previously been demonstrated that inoculum concentration has an impact on the discrepancies observed in microdilution and ADM [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par29">In general, the E-test may overestimate the rates of resistance to antibiotics, but it may be applicable because it showed good agreement with ADM results for levofloxacin, metronidazole, clarithromycin, and tetracycline. However, the disagreement from amoxicillin may require further confirmation.</p></sec><sec id="Sec14"><title>Limitations</title><p id="Par30">One of the limitation of the present study was that no tests were performed in other laboratory centers to check the reproducibility of the methods. The isolates used in this study were collected in 2015 and stored in &#x02212;&#x02009;80&#x000a0;&#x000b0;C. Even though the freeze storage effect on antibiotic sensitivity in <italic>H. pylori</italic> was varied between the studies [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>], it may explain the discrepancy of MIC found in this study. The zero resistance rate for tetracycline also affected the analysis. The number of study samples met the recommendation of CLSI; however, a greater number may have improved the precision of the comparison. Nevertheless, the findings of this study provide the data that E-test was a simple but reliable diagnostic tool for antibiotic-resistant detection in <italic>H. pylori.</italic></p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec15"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13104_2019_4877_MOESM1_ESM.docx"><caption><p><bold>Additional file 1.</bold> Methods explanation. <bold>Figure S1.</bold> Passing&#x02013;Bablok regression of ADM and E-test.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADM</term><def><p id="Par3">agar dilution method</p></def></def-item><def-item><term>AUC</term><def><p id="Par4">area under the curve</p></def></def-item><def-item><term>CLSI</term><def><p id="Par5">Clinical and Laboratory Standards Institute</p></def></def-item><def-item><term>EUCAST</term><def><p id="Par6">European Committee on Antibiotic Susceptibility Testing</p></def></def-item><def-item><term>FDA</term><def><p id="Par7">U.S. Food and Drug Administration</p></def></def-item><def-item><term>MIC</term><def><p id="Par8">minimum inhibitory concentration</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Muhammad Miftahussurur and Kartika Afrida Fauzia contributed equally to this study</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13104-019-4877-9.</p></sec><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>YY, MM, and KAF conceived and designed the study; KAF, MM, LAW, DD, AFS, NR, AK, IKA and JA acquired and summarized the data; MM, KAF, and YY analyzed the data; d DD, IAN, PBS interpreted the data; KAF, MM, and YY wrote the paper; LAW and JA edited and revised the manuscript. All authors read and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by grants from the National Institutes of Health (DK62813) and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of (15H02657, 16H05191, 16H06279, 18KK0266 and 19H03473) (YY) and the&#x000a0;National&#x000a0;Institutes&#x000a0;of&#x000a0;Health&#x000a0;(DK62813). It was also supported by the Japan Society for the Promotion of Science Institutional Program for Core-to-Core Program; B. Africa-Asia Science Platform (YY). LAW, DD, and KAF are doctoral students supported by the MEXT Scholarship Program for 2015, 2016, and 2017, respectively. In addition, the Ministries of Research, Technology, and Higher Education in the World Class Professor Program (123.4/D2.3/KP/2018) supported this research (MM). The funding body had no role in the design of the study and collection, analysis and interpretation of data, and in writing the manuscript.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data sets used and/or analyzed during the current study available from the corresponding author on reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par31">Written informed consent was obtained from all participants, and the protocol was approved by Dr. Cipto Mangunkusumo Teaching Hospital (Jakarta, Indonesia), Dr. Soetomo Teaching Hospital (Surabaya, Indonesia), Dr. Wahidin Sudirohusodo Teaching Hospital (Makassar, Indonesia), and Oita University Faculty of Medicine (Yufu, Japan).</p></notes><notes><title>Consent for publication</title><p id="Par32">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par33">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>El-Omar</surname><given-names>EM</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><etal/></person-group><article-title>Kyoto global consensus report on <italic>Helicobacter pylori</italic> gastritis</article-title><source>Gut</source><year>2015</year><volume>64</volume><issue>9</issue><fpage>1353</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-309252</pub-id><pub-id pub-id-type="pmid">26187502</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>O&#x02019;Morain</surname><given-names>CA</given-names></name><name><surname>Gisbert</surname><given-names>JP</given-names></name></person-group><article-title>Management of <italic>Helicobacter pylori</italic> infection-the Maastricht V/Florence Consensus Report</article-title><source>Gut</source><year>2017</year><volume>66</volume><issue>1</issue><fpage>6</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-312288</pub-id><pub-id pub-id-type="pmid">27707777</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>YT</given-names></name><name><surname>Liou</surname><given-names>JM</given-names></name><name><surname>El-Omar</surname><given-names>EM</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Leow</surname><given-names>AHR</given-names></name><name><surname>Goh</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Primary antibiotic resistance in <italic>Helicobacter pylori</italic> in the Asia-Pacific region: a systematic review and meta-analysis</article-title><source>Lancet Gastroenterol Hepatol.</source><year>2017</year><volume>2</volume><issue>10</issue><fpage>707</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(17)30219-4</pub-id><pub-id pub-id-type="pmid">28781119</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savoldi</surname><given-names>A</given-names></name><name><surname>Carrara</surname><given-names>E</given-names></name><name><surname>Graham</surname><given-names>PDY</given-names></name><name><surname>Conti</surname><given-names>M</given-names></name><name><surname>Tacconelli</surname><given-names>E</given-names></name></person-group><article-title>Prevalence of antibiotic resistance in <italic>Helicobacter pylori</italic>: a systematic review and meta-analysis in World Health Organization regions</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><issue>5</issue><fpage>1372</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.07.007</pub-id><pub-id pub-id-type="pmid">29990487</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageyama</surname><given-names>C</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Sakae</surname><given-names>H</given-names></name><name><surname>Obayashi</surname><given-names>Y</given-names></name><name><surname>Kawahara</surname><given-names>Y</given-names></name><name><surname>Mima</surname><given-names>T</given-names></name><etal/></person-group><article-title>Increase in antibiotic resistant <italic>Helicobacter pylori</italic> in a University Hospital in Japan</article-title><source>Infect Drug Resist.</source><year>2019</year><volume>12</volume><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.2147/IDR.S196452</pub-id><pub-id pub-id-type="pmid">30881065</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miftahussurur</surname><given-names>M</given-names></name><name><surname>Syam</surname><given-names>AF</given-names></name><name><surname>Nusi</surname><given-names>IA</given-names></name><name><surname>Makmun</surname><given-names>D</given-names></name><name><surname>Waskito</surname><given-names>LA</given-names></name><name><surname>Zein</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Surveillance of <italic>Helicobacter pylori</italic> antibiotic susceptibility in Indonesia: different resistance types among regions and with Novel Genetic Mutations</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><issue>12</issue><fpage>e0166199</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0166199</pub-id><pub-id pub-id-type="pmid">27906990</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>CLSI</collab></person-group><source>Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically</source><year>2015</year><edition>10</edition><publisher-loc>Wayne</publisher-loc><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><fpage>M07</fpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdivieso-Garc&#x000ed;a</surname><given-names>A</given-names></name><name><surname>Imgrund</surname><given-names>R</given-names></name><name><surname>Deckert</surname><given-names>A</given-names></name><name><surname>Varughese</surname><given-names>BM</given-names></name><name><surname>Harris</surname><given-names>K</given-names></name><name><surname>Bunimov</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution method in <italic>Campylobacter jejuni</italic> and <italic>Campylobacter coli</italic></article-title><source>Diagn Microbiol Infect Dis</source><year>2009</year><volume>65</volume><issue>2</issue><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2009.07.008</pub-id><pub-id pub-id-type="pmid">19748428</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Clinical and Laboratory Standards Institute</collab></person-group><source>Method comparison and bias estimation using patient samples; approved guideline</source><year>2002</year><publisher-loc>Wayne</publisher-loc><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><fpage>2</fpage></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Lee G-B, Lee S-S, Lee W-b, Chang W-H. Automatic microfluidic system for antibiotic susceptibility testing and method of operating thereof. Google Patents. 2018.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tortorano</surname><given-names>AM</given-names></name><name><surname>Viviani</surname><given-names>MA</given-names></name><name><surname>Barchiesi</surname><given-names>F</given-names></name><name><surname>Arzeni</surname><given-names>D</given-names></name><name><surname>Rigoni</surname><given-names>AL</given-names></name><name><surname>Cogliati</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from oral cavities of AIDS patients</article-title><source>J Clin Microbiol</source><year>1998</year><volume>36</volume><issue>6</issue><fpage>1578</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1128/JCM.36.6.1578-1583.1998</pub-id><pub-id pub-id-type="pmid">9620380</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>LM</given-names></name><name><surname>Haldane</surname><given-names>DJ</given-names></name><name><surname>Keelan</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>DE</given-names></name><name><surname>Thomson</surname><given-names>AB</given-names></name><name><surname>Loo</surname><given-names>V</given-names></name><etal/></person-group><article-title>Multilaboratory comparison of proficiencies in susceptibility testing of <italic>Helicobacter pylori</italic> and correlation between agar dilution and E test methods</article-title><source>Antimicrob Agents Chemother</source><year>2003</year><volume>47</volume><issue>10</issue><fpage>3138</fpage><lpage>3144</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.10.3138-3144.2003</pub-id><pub-id pub-id-type="pmid">14506021</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>SK</given-names></name><name><surname>Gales</surname><given-names>AC</given-names></name><name><surname>Kawakami</surname><given-names>E</given-names></name></person-group><article-title>Antimicrobial susceptibility testing for <italic>Helicobacter pylori</italic> isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion</article-title><source>Braz J Microbiol.</source><year>2014</year><volume>45</volume><issue>4</issue><fpage>1439</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1590/S1517-83822014000400039</pub-id><pub-id pub-id-type="pmid">25763052</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Syam</surname><given-names>AF</given-names></name><name><surname>Miftahussurur</surname><given-names>M</given-names></name><name><surname>Makmun</surname><given-names>D</given-names></name><name><surname>Nusi</surname><given-names>IA</given-names></name><name><surname>Zain</surname><given-names>LH</given-names></name><name><surname>Zulkhairi</surname></name><etal/></person-group><article-title>Risk factors and prevalence of <italic>Helicobacter pylori</italic> in five largest Islands of Indonesia: a preliminary study</article-title><source>PloS ONE.</source><year>2015</year><volume>10</volume><issue>11</issue><fpage>0140186</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0140186</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>JB</given-names></name></person-group><source>Performance standards for antimicrobial susceptibility testing</source><year>2017</year><publisher-loc>Wayne</publisher-loc><publisher-name>Clinical and Laboratory Standards Institute</publisher-name></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Eucast D. DocumentEDEF. 3.1</collab></person-group><article-title>Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution</article-title><source>Clin Microbiol Infect</source><year>2000</year><volume>2000</volume><issue>6</issue><fpage>509</fpage><lpage>515</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bland</surname><given-names>JM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring agreement in method comparison studies</article-title><source>Stat Methods Med Res</source><year>1999</year><volume>8</volume><issue>2</issue><fpage>135</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1177/096228029900800204</pub-id><pub-id pub-id-type="pmid">10501650</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krouwer</surname><given-names>JS</given-names></name></person-group><article-title>Why Bland-Altman plots should use X, not (Y&#x02009;+&#x02009;X)/2 when X is a reference method</article-title><source>Stat Med</source><year>2008</year><volume>27</volume><issue>5</issue><fpage>778</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1002/sim.3086</pub-id><pub-id pub-id-type="pmid">17907247</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Manuilova E, Schuetzenmeister A, Model F. mcr: method comparison regression. R package version 1.2. 1. 2014.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Food</surname><given-names>U</given-names></name><name><surname>Administration</surname><given-names>D</given-names></name></person-group><source>Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA</source><year>2003</year><publisher-loc>Rockville</publisher-loc><publisher-name>US Food Drug Adm</publisher-name></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolomini</surname><given-names>R</given-names></name><name><surname>Di Bonaventura</surname><given-names>G</given-names></name><name><surname>Catamo</surname><given-names>G</given-names></name><name><surname>Carbone</surname><given-names>F</given-names></name><name><surname>Neri</surname><given-names>M</given-names></name></person-group><article-title>Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of <italic>Helicobacter pylori</italic> strains to 20 antimicrobial agents</article-title><source>J Clin Microbiol</source><year>1997</year><volume>35</volume><issue>7</issue><fpage>1842</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1128/JCM.35.7.1842-1846.1997</pub-id><pub-id pub-id-type="pmid">9196205</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alarc&#x000f3;n</surname><given-names>T</given-names></name><name><surname>Domingo</surname><given-names>D</given-names></name><name><surname>L&#x000f3;pez-Brea</surname><given-names>M</given-names></name></person-group><article-title>Discrepancies between E-test and agar dilution methods for testing metronidazole susceptibility of <italic>Helicobacter pylori</italic></article-title><source>J Clin Microbiol</source><year>1998</year><volume>36</volume><issue>4</issue><fpage>1165</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">9542964</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glupczynski</surname><given-names>Y</given-names></name><name><surname>Broutet</surname><given-names>N</given-names></name><name><surname>Cantagrel</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>L</given-names></name><name><surname>Alarcon</surname><given-names>T</given-names></name><name><surname>Lopez-Brea</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of <italic>Helicobacter pylori</italic></article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2002</year><volume>21</volume><issue>7</issue><fpage>549</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1007/s10096-002-0757-6</pub-id><pub-id pub-id-type="pmid">12172749</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osato</surname><given-names>MS</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>SG</given-names></name><name><surname>Penland</surname><given-names>RL</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name></person-group><article-title>Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant <italic>Helicobacter pylori</italic></article-title><source>Int J Antimicrob Agents</source><year>2001</year><volume>17</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0924-8579(00)00320-4</pub-id><pub-id pub-id-type="pmid">11137647</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Testing ECoAS. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. EUCAST, Basel, Switzerland. 2013. <ext-link ext-link-type="uri" xlink:href="http://www.eucast.org/clinical_breakpoints">http://www.eucast.org/clinical_breakpoints</ext-link>.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilic-Zulle</surname><given-names>L</given-names></name></person-group><article-title>Comparison of methods: passing and Bablok regression</article-title><source>Biochemia medica</source><year>2011</year><volume>21</volume><issue>1</issue><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.11613/BM.2011.010</pub-id><pub-id pub-id-type="pmid">22141206</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passing</surname><given-names>H</given-names></name><name><surname>Bablok</surname><given-names>W</given-names></name></person-group><article-title>A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I</article-title><source>Clin Chem Lab Med.</source><year>1983</year><volume>21</volume><issue>11</issue><fpage>709</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1515/cclm.1983.21.11.709</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Recklinghausen</surname><given-names>G</given-names></name><name><surname>Ansorg</surname><given-names>R</given-names></name></person-group><article-title>Metronidazole susceptibility testing of <italic>Helicobacter pylori</italic> with the PDM epsilometer test (E test)</article-title><source>Zentralblatt Bakteriologie.</source><year>1995</year><volume>282</volume><issue>1</issue><fpage>83</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S0934-8840(11)80799-1</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrt</surname><given-names>T</given-names></name><name><surname>Bishop</surname><given-names>J</given-names></name><name><surname>Carlin</surname><given-names>JB</given-names></name></person-group><article-title>Bias, prevalence and kappa</article-title><source>J Clin Epidemiol</source><year>1993</year><volume>46</volume><issue>5</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(93)90018-V</pub-id><pub-id pub-id-type="pmid">8501467</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citron</surname><given-names>DM</given-names></name><name><surname>Ostovari</surname><given-names>M</given-names></name><name><surname>Karlsson</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>E</given-names></name></person-group><article-title>Evaluation of the E test for susceptibility testing of anaerobic bacteria</article-title><source>J Clin Microbiol</source><year>1991</year><volume>29</volume><issue>10</issue><fpage>2197</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.1128/JCM.29.10.2197-2203.1991</pub-id><pub-id pub-id-type="pmid">1939571</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dore</surname><given-names>MP</given-names></name><name><surname>Piana</surname><given-names>A</given-names></name><name><surname>Carta</surname><given-names>M</given-names></name><name><surname>Atzei</surname><given-names>A</given-names></name><name><surname>Are</surname><given-names>BM</given-names></name><name><surname>Mura</surname><given-names>I</given-names></name><etal/></person-group><article-title>Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of <italic>Helicobacter pylori</italic> infection</article-title><source>Aliment Pharmacol Ther</source><year>1998</year><volume>12</volume><issue>7</issue><fpage>635</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1998.00350.x</pub-id><pub-id pub-id-type="pmid">9701526</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>SR</given-names></name><name><surname>Bhakdi</surname><given-names>S</given-names></name><name><surname>Maeurer</surname><given-names>MJ</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Gehring</surname><given-names>S</given-names></name></person-group><article-title>Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy?</article-title><source>J Clin Microbiol</source><year>1999</year><volume>37</volume><issue>8</issue><fpage>2740</fpage><lpage>2741</lpage><pub-id pub-id-type="doi">10.1128/JCM.37.8.2740-2741.1999</pub-id><pub-id pub-id-type="pmid">10405437</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>M&#x000e9;graud</surname><given-names>F</given-names></name><name><surname>Hazell</surname><given-names>S</given-names></name><name><surname>Glupczynski</surname><given-names>Y</given-names></name></person-group><source>Antibiotic susceptibility and resistance. <italic>Helicobacter pylori</italic> physiology and genetics.</source><year>2001</year><publisher-loc>United States</publisher-loc><publisher-name>ASM Press</publisher-name></element-citation></ref></ref-list></back></article>